TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Last Update Posted : 2023-02-17

The aim of this trial is to test licenced drugs in cancers that are not responding to treatment. The drugs tested will depend on the genetics of the cancer. Certain genetic changes are more sensitive to certain drugs. The trial team hope by having a more targeted approach the drugs may be more effective. This trial is open to several cancers including osteosarcoma.

Country: United States,
Locations: Birmingham, Phoenix, Auburn, Berkeley, Los Angeles, Oakland, Palo Alto, Roseville, Sacramento, San Francisco, San Jose, San Leandro, Santa Clara, Santa Cruz, Sunnyvale, Vallejo, Walnut Creek, Bridgeport, Hartford, Meriden, New Britain, Norwich, Torrington, Willimantic, Fort Lauderdale, Fort Myers, Gainesville, Miami, Saint Petersburg, Tallahassee, West Palm Beach, Atlanta, Savannah, Honolulu, Chicago, Indianapolis, Augusta, Belfast, Biddeford, Brewer, Brunswick, Kennebunk, Kittery, Norway, Rockport, Sanford, Scarborough, South Portland, Topsham, Wells, York, Ann Arbor, Brighton, Canton, Chelsea, Detroit, Grand Blanc, Grand Rapids, Kalamazoo, Lansing, Livonia, Pontiac, Saginaw, Traverse City, Warren, Omaha, Concord, Manchester, Portsmouth, Albuquerque, Las Cruces, Rio Rancho, Lake Success, New York, Chapel Hill, Charlotte, Bismarck, Fargo, Cincinnati, Kettering, West Chester, Portland, Allentown, Philadelphia, Bluffton, Hilton Head Island, Sioux Falls, Nashville, Houston, Salt Lake City, Fairfax, Seattle, Burlington, Germantown, Grafton, Green Bay, Kenosha, Marinette, Milwaukee, Oshkosh, Racine, Sheboygan, Summit, Two Rivers, Wauwatosa,
Trial Type: Interventional
Trial Phase: Phase 2,
Trial Status: Recruiting
Minimum age: 12 Years
Maximum age: -
Key Contact: Cindy MacInnis, MBA, Jacqueline Perez, MPH, www.tapur.org, cindy.macinnis@asco.org, jacqueline.perez@asco.org,
Clinical Trial ID: NCT02693535

Genetic testing is used to determine if someone can take part in the trial. The trial is available across multiple centres in the USA.

The treatment given in this trial depends on the cancer’s genetics.
Visit our drugs and interventions page to find out more about this treatment, including how it works and what it’s used for.

The below points are a summary of who can enter the trial.
People who are 12 years of age or older. There are some drugs that may not be available to younger people.
People who have had a sample of tumour analysed to confirm the diagnosis.
People who are not responding to standard treatment or have no other treatment options.
People with cancer that can be measured or evaluated by RECIST v1.1. Your doctor will know this.
People with a ECOG performance status 0-2. Your doctor will know this.
People with adequate liver, kidney, and bone marrow function. You will have tests to check this.
People who have results from a genetic test or immunohistochemistry test for protein expression. It must have been performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. The tests must have been done on a tumour sample or in some cases liquid biopsies. Your doctor will know this.
People who agree to use contraception during the study and 4 months after finishing treatment.

The below points are a summary of who can’t enter the trial.
People who are pregnant.
People with leptomeningeal metastases. This is where cancer has spread to the lining of the brain or spinal cord.
People who are still on steroids for treatment of brain metastasis (must have been off treatment for at least 1 month and not have side effects such as seizures).
Depending on the drug you are eligible for there may be additional criteria.

ONTEX is intended to supplement, not replace, your healthcare team. Patients should always discuss a clinical trial with their healthcare team. If a patient is eligible for a trial the trial team will be able to provide more in-depth information about the trial so the patient can make an informed decision before taking part. Trial information has been sourced from www.clinicaltrials.gov. The content is then reviewed weekly by the Osteosarcoma Now team. All the trials also have a patient-friendly summary and key information section written by the team at Osteosarcoma Now. We have also included a description of the medications being used in the trial and summarised the inclusion and exclusion criteria in the ‘who is this trial (not) for’ sections. To the best of our knowledge the clinical trial database is up-to-date and accurate.However, we cannot assume any liability for the accuracy or completeness of the information.